ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
Acrigen Biosciences Logo

Acrigen Biosciences

At Acrigen, we believe that gene editing will revolutionize medicine and bring hope to millions of patients suffering from genetic diseases. We are developing Precision Gene Editing Systems to harness the power of CRISPR for use in human therapeutics. Acrigen’s proprietary technology leverages novel αCas and μCas CRISPR gene editors coupled with ErAcrs (engineered anti-CRISPR proteins) to create an editing toolbox with best-in-class efficiency and precision. Acrigen has discovered and engineered αCas and μCas, 2 families of novel CRISPR-Cas nucleases fine tuned for human gene editing.

Quick overview

Berkeley, United States

Founded in 2019

1-10 Employees

Additional information

Working industry

Biotechnology

Type of company

Manufacturer

Ownership structure

Privately Held

Locations

1 Headquarter

Number of products

1 Product

Specialised areas

Biotechnology, Genetics, Life Science

Products & services of Acrigen Biosciences

Acrigen Biosciences offers a wide range of products and services

Product: Our Technology — Acrigen Biosciences

Product

Our Technology — Acrigen Biosciences

Go to product >

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

United States


Overall risk estimation:

Low


ESG country scores

The ESG Data of countries are based on public sources

Environment

D

Grade (A-E)

View details

Social

A

Grade (A-E)

View details

Governance

A

Grade (A-E)

View details

Headquarter of Acrigen Biosciences

Acrigen Biosciences operates in 1 country around the world

City: Berkeley

State: California

Country: United States

Locations of Acrigen Biosciences

Get an overview of the locations of Acrigen Biosciences

Location

Country

State

City

Headquarter

United States

California

Berkeley

Frequently asked questions (FAQ) about Acrigen Biosciences

Some frequent questions that have been asked about Acrigen Biosciences

The company headquarter of Acrigen Biosciences is located in Berkeley, California, United States. It's worth noting, that the company may have more locations

As of the latest available information Acrigen Biosciences has around 1-10 employees worldwide.

Acrigen Biosciences was founded in 2019

The company Acrigen Biosciences has it's main focus in the industries of Biotechnology

Competitors of Acrigen Biosciences

Check out some interesting alternative companies to Acrigen Biosciences

Algen Biotechnologies's Logo

Algen Biotechnologies

San Francisco, United States

1-10 Employees

2018

We are on a groundbreaking journey to redefine possibilities in biology. AlgenCRISPR is a proprietary, next-generation CRISPR system developed by Algen. Our best-in-class technology offers robust, fine-tuned and precise gene modulation to deconvolute complex biology. Algen’s proprietary deep learning models are built on billions of real-time, dynamic gene expression changes that occur throughout disease progression.

Emendo Biotherapeutics's Logo

Emendo Biotherapeutics

New York, United States

11-50 Employees

2015

We boldly create novel and elegant CRISPR solutions to make a positive and profound impact on human health. From the very start we knew that CRISPR had the potential to cure the most complex genetic diseases, but limitations of the original CRISPR-Cas9 system prevented this vision from being fully realized. So we flipped the CRISPR script to first understand each genetic disease and then devise an optimal editing strategy. At EmendoBio, we’ve brought together a world class multifaceted team to evolve traditional CRISPR tools and create entirely new nucleases customized to any genetic disease. We come to work knowing every challenge we face can be overcome.

Precision BioSciences's Logo

Precision BioSciences

Durham, United States

101-250 Employees

2006

At Precision BioSciences we are using our novel ARCUS genome editing technology to develop a new class of medicines designed to overcome and potentially cure, hard-to-treat conditions including rare genetic diseases. Our team is built on a foundation of innovation and scientific discovery, and all employees at the company, whom we passionately refer to as Precisioneers, share in our mission – Dedicated to Improving Life – and our values:. ARCUS is a precise and versatile genome editing technology discovered and developed by scientists at Precision BioSciences.

CRISPR Therapeutics's Logo

CRISPR Therapeutics

Cambridge, United States

101-250 Employees

2013

We are pioneering a new era of medicines. We are pioneers of the CRISPR technology and at the forefront of what’s next. The first-ever CRISPR-based therapy is a direct reflection of our patient-forward philosophy. We believe this once-in-a-generation breakthrough will make an impact for generations to come. CRISPR Therapeutics is founded, launching the growth of our team focused on translating the CRISPR/Cas9 discovery into potential therapeutics. Opens the doors to its own manufacturing facility in Framingham, Massachusetts. Where we’ve built our state-of-the-art, award-winning manufacturing facility.*. Here we focus on the most advanced gene editing and delivery technologies of the future.

Scribe Therapeutics's Logo

Scribe Therapeutics

United States

11-50 Employees

2017

Join our mission to engineer the next 20 years of gene editing breakthroughs - today. Pioneering novel viral and non-viral delivery technologies to truly enable in vivo genetic medicine. Built for exceptional specificity within the genome – enabling therapeutic precision and allele specific targeting.

Hunterian Medicine's Logo

Hunterian Medicine

Cambridge, United States

1-10 Employees

2016

The Hunterian technology uses a novel genetic element to enable in vivo delivery via a single adeno-associated virus (AAV). Hunterian Medicine is a gene editing company poised to unleash the full potential of CRISPR. Hunterian Medicine’s technology opens an immediate path to develop cures for a vast number of genetic diseases where no FDA approved therapies exist. Hunterian Medicine’s technology uses a novel “2-for-1” genetic control element, a bidirectional promoter, to overcome the challenge of delivering CRISPR via AAV. Hunterian's approach has the immediate potential to bring multiple CRISPR technologies to the clinic and dramatically accelerate the development of CRISPR-based therapeutics. CRISPR is a revolutionary gene-editing tool with the ability to edit nearly any DNA sequence within the human genome, and the potential to correct a multitude of disease-causing mutations. Our patented platform technology solves the CRISPR delivery problem by enabling efficient, on-target delivery through a single adeno-associated virus (AAV). By freeing up critical space in AAV, Hunterian Medicine’s technology allows for the development of the safest and most effective CRISPR-based therapeutics.